[
  {
    "id": "1768842753563",
    "timestamp": 1768842753563,
    "filename": "scitranslmed 2025 Dermatomyositis is characterized by JAK1-mediatedmonocyte-driven vasculopathy and inflammation.pdf",
    "markdown": "---\naliases: [Dermatomyositis is characterized by JAK1-mediated monocyte-driven vasculopathy and inflammation]\nauthors: Grace A. Osborne, Lin Zhang, Feiyang Ma, J. Michelle Kahlenberg et al.\ntags:\n  - literature\n  - paper\n  - Dermatomyositis\n  - Lupus\n  - scRNA-seq\n  - JAK_inhibitor\n  - Vasculopathy\nyear: 2025\njournal: Science Translational Medicine\ndoi: 10.1126/scitranslmed.aea9007\nstudy_type:\n  - ğŸ”„Hybrid\nproject: Autoimmune Skin Disease Comparison\ndata_accession: GSE303609, GSE186476\ncode_url: N/A\nstatus: unread\ncreated: 2025-12-24 12:00\n---\n\n# Dermatomyositis is characterized by JAK1-mediated monocyte-driven vasculopathy and inflammation\n\n> [!abstract] TL;DR (Executive Summary)\n> **One-sentence summary**: æœ¬ç ”ç©¶åˆ©ç”¨å•ç»†èƒæµ‹åºå¯¹æ¯”äº†çš®è‚Œç‚ï¼ˆDMï¼‰ä¸çº¢æ–‘ç‹¼ç–®ï¼ˆLupusï¼‰çš„çš®è‚¤å¾®ç¯å¢ƒï¼Œå‘ç°çš®è‚Œç‚ç‰¹æœ‰çš„ç‚ç—‡æ€§å•æ ¸ç»†èƒé€šè¿‡åˆ†æ³ŒIL-6ç­‰å› å­é©±åŠ¨å†…çš®ç»†èƒå‘ç”ŸJAK1ä¾èµ–æ€§çš„è¡°è€ä¸å‡‹äº¡ï¼Œä¸”JAKæŠ‘åˆ¶å‰‚å¯æœ‰æ•ˆé€†è½¬è¿™ä¸€è¿‡ç¨‹ã€‚\n> \n\n## 1. Context & Rationale\n- **Research Question**: çš®è‚Œç‚ï¼ˆDermatomyositis, DMï¼‰å’Œç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®ï¼ˆLupusï¼‰è™½ç„¶åœ¨ä¸´åºŠè¡¨ç°å’Œç»„ç»‡ç—…ç†ä¸Šæœ‰é‡å ï¼ˆå¦‚ç•Œé¢çš®ç‚ï¼‰ï¼Œä½†ä¸¤è€…å¯¹æ²»ç–—çš„ååº”ä¸åŒï¼ˆDMçš®è‚¤ç—…å˜å¸¸è¡¨ç°ä¸ºéš¾æ²»æ€§ï¼‰ï¼Œä¸”DMç‰¹æœ‰çš„è¡€ç®¡ç—…å˜æœºåˆ¶å°šä¸æ˜ç¡®ã€‚æœ¬ç ”ç©¶æ—¨åœ¨æ­ç¤ºDMä¸Lupusåœ¨ç»†èƒå’Œåˆ†å­å±‚é¢çš„æ ¹æœ¬å·®å¼‚ã€‚\n- **The Gap**: æ—¢å¾€å…³äºçš®è‚Œç‚å…ç–«å‘ç—…æœºåˆ¶çš„ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨æ ‘çªçŠ¶ç»†èƒå’ŒIFN-Î²ï¼Œä½†å¯¹å…¶ä»–ç»†èƒç¾¤ï¼ˆç‰¹åˆ«æ˜¯å†…çš®ç»†èƒå’Œå•æ ¸ç»†èƒï¼‰åŠå…¶ç›¸äº’ä½œç”¨ç¼ºä¹å…¨é¢äº†è§£ã€‚æ­¤å¤–ï¼Œå°šæ— ç ”ç©¶åœ¨å•ç»†èƒæ°´å¹³ä¸Šç›´æ¥å¹³è¡Œæ¯”è¾ƒDMå’ŒLupusçš„çš®è‚¤ç—…å˜ã€‚\n- **Hypothesis**: çš®è‚Œç‚å…·æœ‰åŒºåˆ«äºLupusçš„ç‹¬ç‰¹åŸºè´¨ç¯å¢ƒå’Œå…ç–«ç»†èƒäºšç¾¤ï¼Œç‰¹åˆ«æ˜¯å•æ ¸ç»†èƒä»‹å¯¼çš„å†…çš®ç»†èƒåŠŸèƒ½éšœç¢æ˜¯å¯¼è‡´å…¶è¡€ç®¡ç—…å˜çš„å…³é”®é©±åŠ¨å› ç´ ï¼Œè€Œè¿™ä¸€è¿‡ç¨‹å¯ä»¥é€šè¿‡é˜»æ–­JAKé€šè·¯æ¥å¹²é¢„ã€‚\n\n## 2. Methodology (Bio + Comp)\n\n### ğŸ’» Dry Lab (In Silico)\n- **Algorithm/Model**: [[Seurat]] (åˆ†ææµç¨‹), [[Harmony]] (æ‰¹æ¬¡æ ¡æ­£), [[CellChat]] & [[CellPhoneDB]] (ç»†èƒé€šè®¯åˆ†æ), [[Ingenuity Pathway Analysis]] (IPA, é€šè·¯åˆ†æ)ã€‚\n- **Datasets**: \n  - çš®è‚Œç‚æ‚£è€… (n=8, é…å¯¹çš®æŸ/éçš®æŸ + PBMCs)ã€‚\n  - çº¢æ–‘ç‹¼ç–®æ‚£è€… (n=11, é…å¯¹çš®æŸ/éçš®æŸ + PBMCs)ã€‚\n  - å¥åº·å¯¹ç…§ (n=8)ã€‚\n  - æ€»ç»†èƒæ•°ï¼š123,150ä¸ªçš®è‚¤ç»†èƒã€‚\n- **Key Parameters**: å·®å¼‚è¡¨è¾¾åŸºå›  (DEGs), ç»†èƒæ¨¡å—è¯„åˆ† (Module scores: IFN-Î±, Senescence, Cytotoxicity)ã€‚\n- **Code Availability**: æœªæä¾›å®šåˆ¶ä»£ç é“¾æ¥ï¼Œä½¿ç”¨æ ‡å‡†æµç¨‹ã€‚\n\n### ğŸ§ª Wet Lab (In Vitro/Vivo)\n- **Samples**: æ‚£è€…çš®è‚¤æ´»æ£€æ ·æœ¬ï¼ˆå†·å†»åˆ‡ç‰‡ï¼‰ã€PBMCsã€åŸä»£è§’è´¨ç»†èƒ (KCs)ã€åŸä»£å†…çš®ç»†èƒ (ECs)ã€‚\n- **Key Assays**: \n  - [[scRNA-seq]] (10x Genomics)ã€‚\n  - [[Immunofluorescence]] (IF): æŸ“è‰² p16, Ki67, VWF, CD207ã€‚\n  - **Ex vivo Skin Explants**: ç¦»ä½“çš®è‚¤å¤–æ¤ä½“è¯ç‰©å¤„ç†ï¼ˆUpadacitinib æˆ– TWEAKæŠ‘åˆ¶å‰‚ï¼‰ã€‚\n  - **Co-culture Killing Assay**: å•æ ¸ç»†èƒä¸å†…çš®ç»†èƒå…±åŸ¹å…»ï¼Œæ£€æµ‹Caspase-3/7å‡‹äº¡ä¿¡å·ã€‚\n- **Validation**: é€šè¿‡IFéªŒè¯å†…çš®ç»†èƒè¡°è€æ ‡å¿—ç‰©ï¼›é€šè¿‡ä½“å¤–å…±åŸ¹å…»å’Œè¯ç‰©é˜»æ–­å®éªŒéªŒè¯å•æ ¸ç»†èƒå¯¹å†…çš®ç»†èƒçš„æ€ä¼¤ä½œç”¨åŠJAKæŠ‘åˆ¶å‰‚çš„æŒ½æ•‘æ•ˆæœã€‚\n\n## 3. Key Results\n\n### Main Findings\n1. **Biological Insight**: \n   - **åŸºè´¨ç¯å¢ƒå·®å¼‚**: DMå’ŒLupuså‡æœ‰Iå‹å¹²æ‰°ç´ ç‰¹å¾ï¼Œä½†DMè§’è´¨ç»†èƒå€¾å‘äºIFN-$\\beta$ååº”ï¼ˆLupusä¸ºIFN-$\\kappa$ï¼‰ï¼Œä¸”DMç‰¹å¼‚æ€§ä¸Šè°ƒIL-18å’ŒVEGFä¿¡å·ã€‚\n   - **å†…çš®ç»†èƒåŠŸèƒ½éšœç¢**: DMçš®æŸä¸­çš„å†…çš®ç»†èƒè¡¨ç°å‡ºæ˜æ˜¾çš„è¡°è€ç‰¹å¾ï¼ˆp16é«˜è¡¨è¾¾ï¼ŒKi67ä½è¡¨è¾¾ï¼‰å’Œå‡‹äº¡å¢åŠ ï¼Œè€ŒLupuså†…çš®ç»†èƒä¸»è¦å—TNFä¿¡å·é©±åŠ¨ã€‚\n   - **è‡´ç—…æ€§å•æ ¸ç»†èƒ**: åœ¨DMè¡€æ¶²å’Œçš®è‚¤ä¸­å‘ç°äº†ä¸€ç¾¤é«˜è¡¨è¾¾ç‚ç—‡å› å­ï¼ˆMono_0äºšç¾¤ï¼ŒCD14+ï¼‰çš„å•æ ¸ç»†èƒï¼Œå®ƒä»¬é€šè¿‡IL-6ã€IL-1$\\beta$ç­‰ä¸å†…çš®ç»†èƒäº’ä½œã€‚\n2. **Technical Metric**: é‰´å®šå‡º11ç§ä¸»è¦çš®è‚¤ç»†èƒç±»å‹ï¼›JAK1æŠ‘åˆ¶å‰‚å¤„ç†åï¼Œå†…çš®ç»†èƒçš„è¡°è€è¯„åˆ†æ˜¾è‘—ä¸‹é™ã€‚\n3. **Clinical Relevance**: è¯å®äº†JAK1æŠ‘åˆ¶å‰‚ï¼ˆUpadacitinibï¼‰ä¸ä»…èƒ½æŠ‘åˆ¶ç‚ç—‡ï¼Œè¿˜èƒ½ç›´æ¥é˜»æ–­å•æ ¸ç»†èƒè¯±å¯¼çš„å†…çš®ç»†èƒæ­»äº¡ï¼Œé€†è½¬è¡€ç®¡ç—…å˜ï¼Œä¸ºéš¾æ²»æ€§çš®è‚Œç‚æä¾›äº†æ²»ç–—ä¾æ®ã€‚\n\n### Key Figures\n| Figure | Description & Takeaway |\n| :--- | :--- |\n| **Fig 1** | **å•ç»†èƒå›¾è°±æ¦‚è§ˆ**ï¼šå±•ç¤ºäº†DMã€Lupuså’Œå¥åº·å¯¹ç…§çš®è‚¤çš„ç»†èƒç»„æˆã€‚å‘ç°DMå’ŒLupusåœ¨è§’è´¨ç»†èƒã€æˆçº¤ç»´ç»†èƒå’Œå†…çš®ç»†èƒæ¯”ä¾‹ä¸Šçš„å¯Œé›†å·®å¼‚ï¼Œå°¤å…¶æ˜¯DMçš®æŸä¸­å†…çš®ç»†èƒå¯Œé›†ã€‚ |\n| **Fig 2** | **è§’è´¨ç»†èƒç»†èƒå› å­ç‰¹å¾**ï¼šDMå’ŒLupuså‡æœ‰IFNç‰¹å¾ï¼Œä½†DMè§’è´¨ç»†èƒç‰¹å¼‚æ€§ä¸Šè°ƒVEGFå’ŒIL-18ä¿¡å·é€šè·¯ã€‚Lupuså€¾å‘äºè¡¨è¾¾*IFNK*ï¼Œè€ŒDMå€¾å‘äº*IFNB*ã€‚ |\n| **Fig 3** | **å†…çš®ç»†èƒè¡°è€ä¸æ¿€æ´»**ï¼šDMå†…çš®ç»†èƒï¼ˆç‰¹åˆ«æ˜¯æ¯›ç»†è¡€ç®¡äºšç¾¤ï¼‰è¡¨ç°å‡ºé«˜æ°´å¹³çš„è¡°è€è¯„åˆ†ï¼ˆSenescence scoreï¼‰å’Œæ°§åŒ–åº”æ¿€ï¼ŒIFæŸ“è‰²è¯å®DMè¡€ç®¡ä¸­p16å‡é«˜ã€Ki67é™ä½ã€‚ |\n| **Fig 6** | **å¤–å‘¨è¡€å•æ ¸ç»†èƒåˆ†æ**ï¼šé‰´å®šå‡ºDMç‰¹æœ‰çš„é«˜ç‚ç—‡æ€§ç»å…¸å•æ ¸ç»†èƒç¾¤ï¼ˆMono_0ï¼‰ï¼Œé«˜è¡¨è¾¾*CXCL1*, *CXCL5*, *FGF2*ï¼Œä¸”è¯¥äºšç¾¤ä¹Ÿå­˜åœ¨äºDMçš®è‚¤ä¸­ã€‚ |\n| **Fig 7** | **æœºåˆ¶éªŒè¯ä¸è¯ç‰©å¹²é¢„**ï¼šç»†èƒé€šè®¯åˆ†ææ˜¾ç¤ºMono_0ä¸å†…çš®ç»†èƒæœ‰å¼ºäº’ä½œã€‚å…±åŸ¹å…»è¯å®DMå•æ ¸ç»†èƒè¯±å¯¼å†…çš®ç»†èƒå‡‹äº¡ã€‚**JAK1æŠ‘åˆ¶å‰‚ï¼ˆUpadacitinibï¼‰å¤„ç†çš®è‚¤å¤–æ¤ä½“å¯æ˜¾è‘—é™ä½å†…çš®ç»†èƒè¡°è€è¯„åˆ†å¹¶é˜»æ–­å‡‹äº¡ã€‚** |\n\n## 4. Critical Analysis (For Grants/Projects)\n\n> [!success] Innovation (For NSFC)\n> *What makes this novel?*\n> 1. **Conceptual**: é¦–æ¬¡åœ¨å•ç»†èƒæ°´å¹³ç³»ç»Ÿæ€§å¯¹æ¯”DMä¸Lupusçš®è‚¤å¾®ç¯å¢ƒï¼Œæ˜ç¡®åŒºåˆ†äº†ä¸¤è€…è™½ç„¶ä¸´åºŠç›¸ä¼¼ä½†åˆ†å­æœºåˆ¶ä¸åŒçš„ç—…ç†ç‰¹å¾ï¼ˆå°¤å…¶æ˜¯IFNäºšå‹åå¥½ï¼šDM-IFN$\\beta$ vs SLE-IFN$\\kappa$ï¼‰ã€‚\n> 2. **Technical**: ç»“åˆäº†ç¦»ä½“çš®è‚¤å¤–æ¤ä½“è¯ç‰©å¤„ç†ï¼ˆEx vivo drug treatmentï¼‰ä¸scRNA-seqï¼Œç›´æ¥åœ¨æ‚£è€…ç»„ç»‡ä¸Šè¯„ä¼°äº†JAKæŠ‘åˆ¶å‰‚å¯¹ç‰¹å®šç»†èƒäºšç¾¤ï¼ˆå¦‚å†…çš®ç»†èƒï¼‰çš„åˆ†å­æ•ˆåº”ï¼Œæ¯”å•çº¯ç»†èƒç³»å®éªŒæ›´å…·ä¸´åºŠè½¬åŒ–ä»·å€¼ã€‚\n\n> [!failure] Limitations & Critiques\n> *Where can I improve upon this?*\n> - **æ ·æœ¬å±€é™æ€§**: æ‰€æœ‰DMæ‚£è€…å‡ä¸ºç™½äººï¼Œç¼ºä¹ç§æ—å¤šæ ·æ€§ï¼›æ ·æœ¬é‡ç›¸å¯¹è¾ƒå°ï¼ˆæ¯ç»„5-11äººï¼‰ã€‚\n> - **ç»†èƒæ•è·é™åˆ¶**: scRNA-seqæœªèƒ½æœ‰æ•ˆæ•è·ä¸­æ€§ç²’ç»†èƒï¼ˆNeutrophilsï¼‰ï¼Œè€Œåœ¨è‡ªèº«å…ç–«æ€§çš®è‚¤ç—…ä¸­ä¸­æ€§ç²’ç»†èƒå¯èƒ½æ‰®æ¼”é‡è¦è§’è‰²ã€‚\n> - **ä½“å†…éªŒè¯**: ç¼ºä¹åŠ¨ç‰©æ¨¡å‹ï¼ˆin vivoï¼‰éªŒè¯ï¼Œä¸»è¦ä¾èµ–ä½“å¤–å…±åŸ¹å…»å’Œç¦»ä½“å¤–æ¤ä½“æ¨¡å‹ã€‚\n\n> [!tip] Relevance to My Research\n> **Connection to [[Vascular Biology]] or [[Autoimmunity]]**:\n> - *Method to adapt*: å€Ÿé‰´å…¶**Ex vivo skin explant + scRNA-seq**çš„å®éªŒè®¾è®¡ï¼Œç”¨äºè¯„ä¼°è¯ç‰©å¯¹ç»„ç»‡å†…ç‰¹å®šç»†èƒé€šè®¯çš„é˜»æ–­æ•ˆæœã€‚\n> - *Idea to steal*: å…³æ³¨**å†…çš®ç»†èƒè¡°è€ï¼ˆEndothelial Senescenceï¼‰**ä½œä¸ºè‡ªèº«å…ç–«ç—…è¡€ç®¡æŸä¼¤çš„é©±åŠ¨å› ç´ ï¼Œå°¤å…¶æ˜¯p16æŸ“è‰²å’Œè¡°è€è¯„åˆ†çš„è®¡ç®—æ–¹æ³•ã€‚\n\n## 5. Manuscript Snippets\n*Useful academic phrases or sentence structures to reference later*\n- \"Dermatomyositis skin lesions have overlapping clinical and histopathological features but show disparate responses to available therapeutics...\" (ç”¨äºå¼•å…¥ç–¾ç—…å¯¹æ¯”)\n- \"Given the limitations of scRNA-seq to detect type I IFNs, we examined IFN expression in primary basal KCs...\" (ç”¨äºè§£é‡Šä¸ºä½•éœ€è¦qPCRéªŒè¯scRNA-seqæ•°æ®)\n- \"Comparison of basal inflammatory KCs in lesional skin revealed a stress response signature... in lupus and enrichment of heat shock proteins... in dermatomyositis.\" (ç”¨äºæè¿°å·®å¼‚åˆ†æç»“æœ)\n\n## 6. References\n- **Related Papers**:\n    - [[Cassius et al., 2020]] (MDA5+ DMä¸IFN-Îºçš„å…³ç³»)\n    - [[Billi et al., 2022]] (Lupuséçš®æŸçš®è‚¤çš„\"Priming\"çŠ¶æ€)\n- **Cited By**:\n    - [[ ]]"
  },
  {
    "id": "1768841862107",
    "timestamp": 1768841862107,
    "filename": "cgt 2024 PANoptosis bridging.pdf",
    "markdown": "---\naliases: [PANoptosis Review 2024]\nauthors: Jie Gao, Anying Xiong, Jiliu Liu, Xiaolan Li, Junyi Wang, Lei Zhang, Yao Liu, Ying Xiong, Guoping Li, Xiang He\ntags:\n  - literature\n  - paper\n  - PANoptosis\n  - Cancer\n  - Immunotherapy\nyear: 2024\njournal: Cancer Gene Therapy\ndoi: 10.1038/s41417-024-00765-9\nstudy_type:\n  - ğŸ”„Hybrid\nproject:\ndata_accession:\ncode_url:\nstatus: unread\ncreated: 2024-05-23 10:00\n---\n\n# PANoptosis: bridging apoptosis, pyroptosis, and necroptosis in cancer progression and treatment\n\n> [!abstract] TL;DR (Executive Summary)\n> **One-sentence summary**: æœ¬ç»¼è¿°è¯¦ç»†é˜è¿°äº†æ³›å‡‹äº¡ï¼ˆPANoptosisï¼‰ä½œä¸ºä¸€ç§æ•´åˆäº†ç»†èƒå‡‹äº¡ã€ç„¦äº¡å’Œåæ­»æ€§å‡‹äº¡çš„ç»†èƒæ­»äº¡æ¨¡å¼ï¼Œåœ¨é‡å¡‘è‚¿ç˜¤å¾®ç¯å¢ƒåŠæŠ—è‚¿ç˜¤å…ç–«æ²»ç–—ä¸­çš„å…³é”®æœºåˆ¶ä¸åº”ç”¨å‰æ™¯ã€‚\n> \n\n## 1. Context & Rationale\n- **Research Question**: ç»†èƒå‡‹äº¡ï¼ˆApoptosisï¼‰ã€ç„¦äº¡ï¼ˆPyroptosisï¼‰å’Œåæ­»æ€§å‡‹äº¡ï¼ˆNecroptosisï¼‰è¿™ä¸‰ç§ç¨‹åºæ€§ç»†èƒæ­»äº¡ï¼ˆPCDï¼‰é€”å¾„å¦‚ä½•åœ¨ç™Œç—‡ä¸­ç›¸äº’ä½œç”¨ï¼Ÿè¿™ç§äº’ä½œï¼ˆå³æ³›å‡‹äº¡ PANoptosisï¼‰å¦‚ä½•å½±å“è‚¿ç˜¤å¾®ç¯å¢ƒï¼ˆTMEï¼‰åŠæ²»ç–—ååº”ï¼Ÿ\n- **The Gap**: æ—¢å¾€ç ”ç©¶å¤šèšç„¦äºå•ä¸€çš„ç»†èƒæ­»äº¡é€”å¾„ï¼Œä½†ç™Œç»†èƒå¸¸é€šè¿‡æ—è·¯æœºåˆ¶é€ƒé¿å•ä¸€æ­»äº¡æ¨¡å¼ã€‚å¯¹äºè¿™ä¸‰ç§é€”å¾„å¦‚ä½•é€šè¿‡â€œæ³›å‡‹äº¡ä½“ï¼ˆ[[PANoptosome]]ï¼‰â€å¤åˆä½“è¿›è¡Œä¸²æ‰°ï¼ˆCrosstalkï¼‰ï¼ŒåŠå…¶åœ¨ä¸åŒç™Œç§ä¸­çš„å…·ä½“åŒé‡ä½œç”¨ï¼ˆä¿ƒç™Œ vs æŠ‘ç™Œï¼‰ç¼ºä¹ç³»ç»Ÿæ€§çš„æ•´åˆè®ºè¿°ã€‚\n- **Hypothesis**: æ³›å‡‹äº¡ä¸ä»…ä»…æ˜¯å¤šç§æ­»äº¡æ–¹å¼çš„ç®€å•å åŠ ï¼Œè€Œæ˜¯ä¸€ä¸ªç”±å…³é”®åˆ†å­ï¼ˆå¦‚ [[ZBP1]]ã€[[RIPK1]]/[[RIPK3]]ã€[[Caspase-8]]ï¼‰ä¸¥å¯†è°ƒæ§çš„æ•´åˆç½‘ç»œï¼Œæ¿€æ´»æ³›å‡‹äº¡å¯ä»¥å…‹æœè‚¿ç˜¤å¯¹å•ä¸€æ­»äº¡æ–¹å¼çš„è€è¯æ€§ï¼Œå¹¶æ¿€å‘å¼ºçƒˆçš„æŠ—è‚¿ç˜¤å…ç–«ååº”ã€‚\n\n## 2. Methodology (Bio + Comp)\n*æ³¨ï¼šæœ¬æ–‡ä¸ºç»¼è¿°æ–‡ç« ï¼Œä»¥ä¸‹æ€»ç»“äº†æ–‡ä¸­å¼•ç”¨çš„ç ”ç©¶ä¸»è¦é‡‡ç”¨çš„æ–¹æ³•å­¦ã€‚*\n\n### ğŸ’» Dry Lab (In Silico)\n- **Algorithm/Model**: ä¸»è¦æ˜¯ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æï¼Œç”¨äºæ„å»ºé¢„åæ¨¡å‹ã€‚åŒ…æ‹¬ [[Cox Regression]]ã€[[Lasso Regression]] ä»¥åŠæœºå™¨å­¦ä¹ ç®—æ³•ï¼ˆå¦‚äººå·¥ç¥ç»ç½‘ç»œ [[ANN]]ï¼‰ã€‚\n- **Datasets**: [[TCGA]] (The Cancer Genome Atlas) ç”¨äºåˆ†ææ³›å‡‹äº¡ç›¸å…³åŸºå› ï¼ˆPRGsï¼‰çš„è¡¨è¾¾ä¸ç”Ÿå­˜ç‡çš„ç›¸å…³æ€§ï¼›[[GEO]] æ•°æ®åº“ã€‚\n- **Key Parameters**: PANoptosis Score (æ³›å‡‹äº¡è¯„åˆ†), Immune Infiltration Levels (ä½¿ç”¨ [[CIBERSORT]] ç®—æ³•ä¼°ç®—)ã€‚\n\n### ğŸ§ª Wet Lab (In Vitro/Vivo)\n- **Samples**: å„ç±»ç™Œç»†èƒç³»ï¼ˆå¦‚ lung, gastric, HCC, breast cancer cell linesï¼‰ã€åŸºå› æ•²é™¤å°é¼ æ¨¡å‹ï¼ˆå¦‚ [[NLRP3]]-/- å°é¼ , [[ZBP1]] ç¼ºå¤±æ¨¡å‹ï¼‰ã€‚\n- **Key Assays**: \n    - **åˆ†å­æœºåˆ¶**: [[Western Blot]] (æ£€æµ‹ Caspases, GSDMD, MLKL ç£·é…¸åŒ–), [[Co-IP]] (æ£€æµ‹ PANoptosome å¤åˆä½“ç»„è£…)ã€‚\n    - **ç»†èƒåŠŸèƒ½**: [[Flow Cytometry]] (æ£€æµ‹ç»†èƒæ­»äº¡), [[ELISA]] (æ£€æµ‹ IL-1Î², IL-18 ç­‰ç»†èƒå› å­)ã€‚\n    - **ä½“å†…å®éªŒ**: å¼‚ç§ç§»æ¤ç˜¤æ¨¡å‹ï¼Œè¯±å¯¼æ€§ç»“è‚ ç™Œæ¨¡å‹ (AOM/DSS)ã€‚\n- **Validation**: é€šè¿‡æ•²ä½æˆ–è¿‡è¡¨è¾¾å…³é”®åŸºå› ï¼ˆå¦‚ [[FADD]], [[GSDME]]ï¼‰éªŒè¯å…¶å¯¹è‚¿ç˜¤å¢æ®–å’Œå…ç–«ç»†èƒæµ¸æ¶¦çš„å½±å“ã€‚\n\n## 3. Key Results\n\n### Main Findings\n1. **Biological Insight**: ç¡®è®¤äº† **[[PANoptosome]]** ä½œä¸ºè°ƒæ§ä¸­å¿ƒï¼Œèƒ½å¤ŸåŒæ—¶æˆ–äº¤æ›¿æ¿€æ´»ç»†èƒå‡‹äº¡ã€ç„¦äº¡å’Œåæ­»æ€§å‡‹äº¡ã€‚å…³é”®çš„åˆ†å­å¼€å…³åŒ…æ‹¬ [[Caspase-8]]ï¼ˆä½œä¸ºéç‚æ€§ä¸ç‚æ€§æ­»äº¡çš„åˆ‡æ¢ç‚¹ï¼‰å’Œ [[RIPK1]]/[[RIPK3]] è½´ã€‚\n2. **Clinical Relevance**: æ³›å‡‹äº¡ç›¸å…³åŸºå› ï¼ˆPRGsï¼‰åœ¨å¤šç§ç™Œç—‡ï¼ˆè‚ºç™Œã€æ¶ˆåŒ–ç³»ç»Ÿç™Œç—‡ã€èƒ¶è´¨ç˜¤ç­‰ï¼‰ä¸­è¡¨ç°å‡ºæ˜¾è‘—çš„é¢„åä»·å€¼ã€‚ä¾‹å¦‚ï¼Œ[[ZBP1]] å’Œ [[RIPK3]] çš„è¡¨è¾¾é€šå¸¸ä¸æ›´å¥½çš„æŠ—è‚¿ç˜¤å…ç–«ååº”ç›¸å…³ã€‚\n3. **Immunological Impact**: æ³›å‡‹äº¡å…·æœ‰é«˜åº¦å…ç–«åŸæ€§ï¼Œé‡Šæ”¾ ATPã€HMGB1 ç­‰æŸä¼¤ç›¸å…³åˆ†å­æ¨¡å¼ï¼ˆ[[DAMPs]]ï¼‰å’Œç»†èƒå› å­ï¼ˆIL-1Î², TNF-Î±ï¼‰ï¼Œä»è€Œå‹Ÿé›† [[CD8+ T Cells]] å’Œ [[NK Cells]]ï¼Œå°†â€œå†·â€è‚¿ç˜¤è½¬å˜ä¸ºâ€œçƒ­â€è‚¿ç˜¤ã€‚\n\n### Key Figures\n| Figure | Description & Takeaway |\n| :--- | :--- |\n| **Fig 1** | **ä¸‰ç§ç»†èƒæ­»äº¡é€”å¾„çš„åˆ†å­æœºåˆ¶**ã€‚åˆ†åˆ«å±•ç¤ºäº†ç»†èƒå‡‹äº¡ï¼ˆIntrinsic/Extrinsicï¼‰ã€ç„¦äº¡ï¼ˆ[[NLRP3]]/[[GSDMD]]ï¼‰å’Œåæ­»æ€§å‡‹äº¡ï¼ˆ[[RIPK1]]/[[RIPK3]]/[[MLKL]]ï¼‰çš„ç»å…¸é€šè·¯ã€‚ |\n| **Fig 2** | **æ³›å‡‹äº¡ä¸­çš„ä¸²æ‰°äº‹ä»¶ï¼ˆCrosstalkï¼‰**ã€‚å±•ç¤ºäº† [[PANoptosome]] å¤åˆä½“å¦‚ä½•æ•´åˆä¸Šæ¸¸ä¿¡å·ï¼Œä»¥åŠ [[Caspase]] å®¶æ—å’Œ [[RIPK]] å®¶æ—å¦‚ä½•åœ¨ä¸åŒé€šè·¯é—´è¿›è¡Œä¿¡å·åˆ‡æ¢ï¼ˆä¾‹å¦‚ Caspase-8 æŠ‘åˆ¶åæ­»æ€§å‡‹äº¡ä½†ä¿ƒè¿›å‡‹äº¡å’Œç„¦äº¡ï¼‰ã€‚ |\n| **Fig 3** | **æ³›å‡‹äº¡åœ¨æŠ—è‚¿ç˜¤å…ç–«ä¸­çš„ä½œç”¨**ã€‚æç»˜äº† TME ä¸­è‚¿ç˜¤ç»†èƒå‘ç”Ÿæ³›å‡‹äº¡åï¼Œé‡Šæ”¾çš„ç»†èƒå› å­å’ŒæŠ—åŸå¦‚ä½•æ¿€æ´» [[Macrophages]]ã€[[DC Cells]]ã€[[NK Cells]] å’Œ [[CD8+ T Cells]]ï¼Œå½¢æˆæ­£åé¦ˆå¾ªç¯æ€ä¼¤è‚¿ç˜¤ã€‚ |\n| **Fig 4** | **é¶å‘æ³›å‡‹äº¡çš„ç™Œç—‡æ²»ç–—ç­–ç•¥**ã€‚æ€»ç»“äº†é’ˆå¯¹å…³é”®é¶ç‚¹ï¼ˆ[[ZBP1]], [[Caspases]], [[NLRP3]], [[RIPK1]]/[[RIPK3]]ï¼‰çš„è¯ç‰©å¼€å‘ç­–ç•¥ï¼Œä»¥åŠåˆ©ç”¨çº³ç±³é¢—ç²’ï¼ˆNanoparticlesï¼‰è¯±å¯¼æ³›å‡‹äº¡çš„æ–°å…´ç–—æ³•ã€‚ |\n\n## 4. Critical Analysis (For Grants/Projects)\n\n> [!success] Innovation (For NSFC)\n> *What makes this novel?*\n> 1. **Conceptual**: å¼ºè°ƒäº† **PANoptosis** ä½œä¸ºä¸€ä¸ªç»Ÿä¸€çš„æ•´ä½“æ¦‚å¿µï¼Œè€Œä¸æ˜¯å­¤ç«‹çš„é€šè·¯ã€‚ç‰¹åˆ«æ˜¯æŒ‡å‡ºäº† [[ZBP1]] ä½œä¸ºè¿™ä¸€è¿‡ç¨‹çš„â€œä¸»å¼€å…³ï¼ˆMaster Switchï¼‰â€åœ¨æ„ŸçŸ¥ç—…æ¯’å’Œè‚¿ç˜¤ä¿¡å·ä¸­çš„åŒé‡è§’è‰²ã€‚\n> 2. **Therapeutic**: æå‡ºäº†â€œå…ç–«åŸæ€§æ³›å‡‹äº¡ï¼ˆImmunogenic PANoptosisï¼‰â€ä½œä¸ºå…‹æœä¼ ç»ŸåŒ–ç–—è€è¯å’Œå…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ï¼ˆICBï¼‰æ— å“åº”çš„æ–°ç­–ç•¥ã€‚\n\n> [!failure] Limitations & Critiques\n> *Where can I improve upon this?*\n> - **Context Dependency**: æ–‡ä¸­æåˆ°æ³›å‡‹äº¡åœ¨æŸäº›æƒ…å†µä¸‹å¯èƒ½ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ï¼ˆå¦‚æ…¢æ€§ç‚ç—‡å¯¼è‡´çš„ç»„ç»‡æŸä¼¤ä¿®å¤ååº”ï¼‰ï¼Œä½†å…·ä½“çš„åˆ†å­ç•Œé™ï¼ˆä½•æ—¶æŠ‘ç™Œ vs ä½•æ—¶ä¿ƒç™Œï¼‰å°šä¸å®Œå…¨æ˜ç¡®ã€‚\n> - **Drug Specificity**: ç›®å‰é’ˆå¯¹ PANoptosome ç»„åˆ†çš„ç‰¹å¼‚æ€§è¯ç‰©å¤§å¤šå¤„äºä¸´åºŠå‰é˜¶æ®µï¼Œè„±é¶æ•ˆåº”ï¼ˆOff-target effectsï¼‰ä»æ˜¯æŒ‘æˆ˜ã€‚\n> - **In Vivo Complexity**: å¤§å¤šæ•°æœºåˆ¶ç ”ç©¶åŸºäºç»†èƒç³»æˆ–å°é¼ æ¨¡å‹ï¼Œäººä½“ TME çš„å¤æ‚æ€§å¯èƒ½å¯¼è‡´æ³›å‡‹äº¡è¯±å¯¼å‰‚çš„æ•ˆæœä¸å¦‚é¢„æœŸã€‚\n\n> [!tip] Relevance to My Research\n> **Connection to [[FBN1]] or [[SPP1]]**:\n> - *Idea to steal*: å¦‚æœç ”ç©¶ [[SPP1]] (Osteopontin) åœ¨ TME ä¸­çš„ä½œç”¨ï¼Œå¯ä»¥æ¢ç©¶å…¶æ˜¯å¦é€šè¿‡è°ƒèŠ‚ [[NF-ÎºB]] é€šè·¯é—´æ¥å½±å“ [[RIPK1]]/[[Caspase-8]] çš„è¡¨è¾¾ï¼Œä»è€ŒæŠ‘åˆ¶æ³›å‡‹äº¡ä»¥ç»´æŒè‚¿ç˜¤å­˜æ´»ã€‚\n> - *Method to adapt*: å¯ä»¥å‚è€ƒæ–‡ä¸­æåˆ°çš„æ„å»ºâ€œæ³›å‡‹äº¡ç›¸å…³åŸºå› é¢„åæ¨¡å‹ï¼ˆPANoptosis-based prognostic modelï¼‰â€çš„æ–¹æ³•ï¼Œåˆ†ææ„Ÿå…´è¶£çš„åŸºå› é›†ä¸æ³›å‡‹äº¡è¯„åˆ†çš„ç›¸å…³æ€§ã€‚\n\n## 5. Manuscript Snippets\n*Useful academic phrases or sentence structures to reference later*\n- \"PANoptosis, a convergence of apoptosis, pyroptosis, and necroptosis, plays a crucial role in cell death and immune response regulation.\" (å®šä¹‰å¥)\n- \"The progression of cancer has been linked to mechanisms that allow cancer cells to bypass PANoptosis.\" (æœºåˆ¶èƒŒæ™¯)\n- \"It highlights the significant role of PANoptosis in various cancers... showing its impact on tumorigenesis and patient survival rates.\" (ä¸´åºŠæ„ä¹‰)\n\n## 6. References\n- **Related Papers**:\n    - [[Malireddi RKS, 2019]] (ZBP1 and TAK1: master regulators of PANoptosis)\n    - [[Christgen S, 2020]] (Identification of the PANoptosome)\n    - [[Karki R, 2021]] (ADAR1 and ZBP1 in innate immunity and cell death)\n- **Cited By**:\n    - [[ ]] (N/A for this new review)"
  },
  {
    "id": "1768840505771",
    "timestamp": 1768840505771,
    "filename": "Circ Res 2026 schwartzman-et-al-2026-decoding-vascular-cell-diversity-single-cell-approaches-to-mechanisms-of-vascular-disease.pdf",
    "markdown": "---\naliases:\n  - Decoding Vascular Cell Diversity\n  - Vascular Single-Cell Review 2026\nauthors:\n  - William E. Schwartzman\n  - Jiahao Jiang\n  - Jathin S. Rao\n  - Gavin Schnitzler\n  - Mohita Maurya\n  - Lily Widdup\n  - Mark E. Pepin\n  - Helen Kang\n  - Cindy Zheng\n  - Rajat M. Gupta\ntags:\n  - literature\n  - paper\n  - vascular_biology\n  - single_cell\n  - review\nyear: 2026\njournal: Circulation Research\ndoi: 10.1161/CIRCRESAHA.125.326001\nstudy_type:\n  - ğŸ§ªExperimental\n  - ğŸ’»Computational\n  - ğŸ”„Hybrid\nproject: Vascular Disease Mechanisms\ndata_accession: Human Cell Atlas, Broad Single Cell Portal\ncode_url: N/A\nstatus: unread\ncreated: 2026-01-02 12:00\n---\n\n# Decoding Vascular Cell Diversity: Single-Cell Approaches to Mechanisms of Vascular Disease\n\n> [!abstract] TL;DR (Executive Summary)\n> **One-sentence summary**: æœ¬ç»¼è¿°è¯¦ç»†é˜è¿°äº†å•ç»†èƒæŠ€æœ¯ï¼ˆå¦‚ [[scRNA-seq]]ã€[[snRNA-seq]]ã€[[Spatial Transcriptomics]] å’Œ [[Perturb-seq]]ï¼‰çš„å‘å±•å†ç¨‹åŠå…¶åœ¨è§£æè¡€ç®¡ç»†èƒå¼‚è´¨æ€§ã€åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–æœºåˆ¶ä»¥åŠé€šè¿‡ GWAS å˜å¼‚å…³è”å‘ç°æ–°æ²»ç–—é¶ç‚¹ä¸­çš„å…³é”®ä½œç”¨ã€‚\n\n## 1. Context & Rationale\n- **Research Question**: å•ç»†èƒæŠ€æœ¯å¦‚ä½•å…‹æœä¼ ç»Ÿç»„ç»‡å­¦å’Œæ‰¹é‡æµ‹åºçš„å±€é™æ€§ï¼Œä»è€Œåœ¨å•ç»†èƒåˆ†è¾¨ç‡ä¸‹æ­ç¤ºè¡€ç®¡ç–¾ç—…ï¼ˆå¦‚ CADã€åŠ¨è„‰ç˜¤ï¼‰çš„ç»†èƒå¼‚è´¨æ€§ã€åŠ¨æ€çŠ¶æ€åŠè‡´ç—…æœºåˆ¶ï¼Ÿ\n- **The Gap**: è¿‡å»çš„ç ”ç©¶ä¸»è¦ä¾èµ–äºæ‰¹é‡åˆ†æï¼ˆBulk Analysisï¼‰ï¼Œæ©ç›–äº†è¡€ç®¡ç»„ç»‡ä¸­å¤æ‚çš„ç»†èƒå¼‚è´¨æ€§ï¼ˆHeterogeneityï¼‰ï¼Œéš¾ä»¥è¯†åˆ«ç¨€æœ‰ç»†èƒç¾¤ï¼ˆå¦‚å¹²ç»†èƒæ ·ç»†èƒï¼‰ä»¥åŠç–¾ç—…ç‰¹å¼‚æ€§çš„ç»†èƒçŠ¶æ€è½¬å˜ï¼ˆå¦‚ SMC è¡¨å‹è½¬æ¢ï¼‰ã€‚\n- **Hypothesis**: é€šè¿‡é«˜é€šé‡å•ç»†èƒæµ‹åºç»“åˆ CRISPR æ‰°åŠ¨ï¼ˆPerturbationï¼‰å’Œç©ºé—´è½¬å½•ç»„å­¦ï¼Œå¯ä»¥ç²¾ç¡®ç»˜åˆ¶è¡€ç®¡ç–¾ç—…çš„ç»†èƒå›¾è°±ï¼Œå¹¶å°†äººç±»é—ä¼ å­¦æ•°æ®ï¼ˆGWASï¼‰ä¸å…·ä½“çš„ç»†èƒåˆ†å­æœºåˆ¶è”ç³»èµ·æ¥ã€‚\n\n## 2. Methodology (Bio + Comp)\n\n*æœ¬ç¯‡ä¸ºç»¼è¿°æ–‡ç« ï¼Œæ€»ç»“äº†è¯¥é¢†åŸŸä½¿ç”¨çš„ä¸»è¦æŠ€æœ¯å’Œæ–¹æ³•ã€‚*\n\n### ğŸ’» Dry Lab (In Silico)\n- **Algorithm/Model**: \n    - é¢„å¤„ç†ä¸å®šé‡: [[Cell Ranger]], [[STARsolo]], [[Salmon/Alevin]], [[UMI-tools]].\n    - é™ç»´ä¸èšç±»: [[PCA]], [[t-SNE]], [[UMAP]], [[Louvain]], [[Leiden]].\n    - å»æ‰¹æ¬¡æ•ˆåº”: [[Harmony]], [[scVI]], [[MNN Correct]], [[Seurat Integration]].\n    - è½¨è¿¹æ¨æ–­ (Trajectory Inference): [[Monocle]], [[RNA velocity]] (scVelo), [[CellRank]].\n    - é—ä¼ å…³è”åˆ†æ: [[MAGMA]], [[scDRS]], [[ECLIPSER]] (ç”¨äºè¿æ¥ GWAS ä¿¡å·ä¸ç»†èƒç±»å‹).\n- **Datasets**: [[Human Cell Atlas]], Broad Institute Single Cell Portal, CZ Cell x Gene.\n\n### ğŸ§ª Wet Lab (In Vitro/Vivo)\n- **Samples**: å°é¼ /äººç±»ä¸»åŠ¨è„‰ç»„ç»‡ (Aorta), å† çŠ¶åŠ¨è„‰ (Coronary Artery), åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–æ–‘å— (Plaque), è„‘è¡€ç®¡ç­‰ã€‚\n- **Key Assays**: \n    - **æ ¸å¿ƒæŠ€æœ¯**: [[scRNA-seq]] (Drop-seq, 10x Genomics), [[snRNA-seq]] (é€‚ç”¨äºå†·å†»/éš¾è§£ç¦»ç»„ç»‡).\n    - **è¡¨è§‚é—ä¼ **: [[scATAC-seq]], [[scMultiome]] (RNA + ATAC).\n    - **ç©ºé—´æŠ€æœ¯**: [[Visium]], [[Xenium]], [[MERFISH]], [[Slide-seq]].\n    - **åŠŸèƒ½éªŒè¯**: [[Perturb-seq]] (CRISPR screening + scRNA-seq readout).\n\n## 3. Key Results\n\n### Main Findings\n1. **Biological Insight (å†…çš®ç»†èƒ ECs)**: æ­ç¤ºäº†ç”±è§£å‰–ä½ç½®ï¼ˆå™¨å®˜ç‰¹å¼‚æ€§ï¼‰å’Œè¡€æµå‰ªåˆ‡åŠ›ï¼ˆShear Stressï¼‰é©±åŠ¨çš„ EC å¼‚è´¨æ€§ã€‚ä¾‹å¦‚ï¼Œåœ¨å°é¼ ä¸»åŠ¨è„‰ä¸­é‰´å®šå‡ºå—æ‰°åŠ¨æµè¯±å¯¼çš„ EC äºšç¾¤ï¼Œä»¥åŠå† çŠ¶åŠ¨è„‰ä¸­è°ƒæ§è¡€ç®¡å¼ åŠ›çš„ [[CD133]]+[[TRPV4]]high ç»†èƒç¾¤ã€‚\n2. **Biological Insight (å¹³æ»‘è‚Œç»†èƒ SMCs)**: è¯å®äº† SMC åœ¨åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­çš„â€œè¡¨å‹è½¬æ¢â€ï¼ˆPhenotypic Switchingï¼‰ã€‚SMC å¯è½¬åŒ–ä¸ºçº¤ç»´è‚Œç»†èƒï¼ˆFibromyocytes, å— [[TCF21]] è°ƒæ§ï¼Œå…·æœ‰ä¿æŠ¤æ€§ï¼‰æˆ–å·¨å™¬ç»†èƒæ ·/è½¯éª¨ç»†èƒæ ·ç»†èƒã€‚\n3. **Biological Insight (å…ç–«ç»†èƒ)**: åœ¨æ–‘å—ä¸­é‰´å®šäº† [[TREM2]] é«˜è¡¨è¾¾çš„è„‚è´¨ç›¸å…³å·¨å™¬ç»†èƒï¼ˆLAMsï¼‰ï¼Œè¿™äº›ç»†èƒæœ€åˆè¢«è®¤ä¸ºå…·æœ‰æŠ—ç‚ä½œç”¨ï¼Œä½†è¿‘æœŸç ”ç©¶æ˜¾ç¤ºå…¶å…·æœ‰ä¿ƒç‚å¯å¡‘æ€§ã€‚åŒæ—¶æ­ç¤ºäº†æ–‘å—ä¸­ T ç»†èƒçš„è€—ç«­å’Œè‡ªèº«å…ç–«ç‰¹å¾ã€‚\n4. **Technical Progress**: [[Perturb-seq]] æ­£åœ¨æˆä¸ºè¿æ¥ GWAS å˜å¼‚ä¸åŠŸèƒ½çš„æ¡¥æ¢ã€‚ä¾‹å¦‚ï¼Œé€šè¿‡åœ¨å†…çš®ç»†èƒä¸­å¹²æ‰° CAD ç›¸å…³åŸºå› ï¼Œå‘ç° [[CCM]] (Cerebral Cavernous Malformation) ä¿¡å·é€šè·¯çš„ä¸‹è°ƒåè€Œä¸ CAD é£é™©é™ä½ç›¸å…³ã€‚\n\n### Key Figures\n| Figure | Description & Takeaway |\n| :--- | :--- |\n| **Fig 1** | **scRNA-seq æŠ€æœ¯æ—¶é—´çº¿**ï¼šå±•ç¤ºäº†ä»å•ç»†èƒæ‰‹åŠ¨æŒ‘é€‰åˆ°åŸºäºæ¶²æ»´ï¼ˆDroplet-basedï¼‰å’Œç»„åˆç´¢å¼•ï¼ˆCombinatorial Indexingï¼‰æŠ€æœ¯å¸¦æ¥çš„é€šé‡æŒ‡æ•°çº§å¢é•¿ã€‚ |\n| **Fig 2** | **scRNA-seq æµç¨‹æ¦‚è§ˆ**ï¼šæ€»ç»“äº†ä»ç»„ç»‡è§£ç¦»ã€æ¶²æ»´ç”Ÿæˆã€æµ‹åºåˆ°ä¸‹æ¸¸é™ç»´ã€èšç±»å’Œè½¨è¿¹åˆ†æçš„æ ‡å‡†è®¡ç®—æµç¨‹ã€‚ |\n| **Fig 3** | **scRNA-seq vs snRNA-seq**ï¼šæ¯”è¾ƒäº†ä¸¤ç§æ–¹æ³•ã€‚snRNA-seq é€‚ç”¨äºå†·å†»æ ·æœ¬å’Œéš¾è§£ç¦»ç»„ç»‡ï¼ˆå¦‚å¿ƒè„ï¼‰ï¼Œåå·®è¾ƒå°ï¼Œä½†çµæ•åº¦è¾ƒä½ï¼ˆä¸»è¦æ•è·æ ¸å†… RNAï¼‰ã€‚ |\n| **Fig 4** | **è¡€ç®¡ç»†èƒå›¾è°±æ¦‚è§ˆ**ï¼šåˆ—ä¸¾äº†è¿‘æœŸå…³äºäººç±»å’Œå°é¼ ä¸åŒè¡€ç®¡åºŠï¼ˆè„‘ã€è‚ºã€å¤§è¡€ç®¡ï¼‰çš„é‡Œç¨‹ç¢‘å¼å•ç»†èƒç ”ç©¶ã€‚ |\n| **Fig 5** | **å†…çš®ç»†èƒå¼‚è´¨æ€§**ï¼šå±•ç¤ºäº†å°é¼ ä¸»åŠ¨è„‰ EC çš„ä¸‰ä¸ªäºšç¾¤ï¼Œå…¶ä¸­ EC2 ä½äºæ‰°åŠ¨æµåŒºåŸŸï¼Œè¡¨è¾¾è„‚è›‹ç™½å¤„ç†ç›¸å…³åŸºå› ï¼›EC1 ä½äºå±‚æµåŒºã€‚ |\n| **Fig 6** | **ä¸‰å¤§è¡€ç®¡ç»†èƒç±»å‹äºšç¾¤**ï¼šæ€»ç»“äº† SMCï¼ˆæ”¶ç¼©å‹ã€åˆæˆå‹ã€çº¤ç»´è‚Œç»†èƒç­‰ï¼‰ã€ECï¼ˆç®¡è…”ã€å¾®è¡€ç®¡ã€æ·‹å·´ï¼‰å’Œå·¨å™¬ç»†èƒï¼ˆ[[TREM2]]+ LAMs, é©»ç•™å‹ç­‰ï¼‰çš„å¤šæ ·æ€§ã€‚ |\n| **Fig 7** | **Perturb-seq åº”ç”¨**ï¼šå±•ç¤ºäº†åˆ©ç”¨ Perturb-seq ç­›é€‰ 241 ä¸ª CAD GWAS ä½ç‚¹é™„è¿‘çš„åŸºå› ï¼Œé€šè¿‡â€œå˜å¼‚-åŸºå› -ç¨‹åºâ€æ¨æ–­ï¼Œå‘ç° EC ä¸­ CCM ä¿¡å·é€šè·¯ä¸ CAD é£é™©çš„å…³è”ã€‚ |\n\n## 4. Critical Analysis (For Grants/Projects)\n\n> [!success] Innovation (For NSFC)\n> *What makes this novel?*\n> 1. **Conceptual**: æå‡ºäº†ä»å•çº¯çš„â€œç»†èƒå›¾è°±ç»˜åˆ¶â€å‘â€œæœºåˆ¶è§£æâ€è½¬å˜çš„èŒƒå¼ï¼Œç‰¹åˆ«æ˜¯åˆ©ç”¨ [[Perturb-seq]] å°†é—ä¼ é£é™©ä½ç‚¹ï¼ˆGWASï¼‰ç›´æ¥æ˜ å°„åˆ°ç»†èƒç‰¹å¼‚æ€§çš„è½¬å½•ç¨‹åºï¼ˆTranscriptional Programsï¼‰ã€‚\n> 2. **Technical**: å¼ºè°ƒäº†å¤šç»„å­¦æ•´åˆï¼ˆMultiomicsï¼‰å’Œç©ºé—´è½¬å½•ç»„ï¼ˆSpatial Transcriptomicsï¼‰åœ¨è§£å†³è¡€ç®¡ç»„ç»‡ç»“æ„å¤æ‚æ€§ä¸­çš„åº”ç”¨ï¼Œç‰¹åˆ«æ˜¯è§£å†³äº†ä¼ ç»Ÿè§£ç¦»æ–¹æ³•ä¸¢å¤±ç©ºé—´ä¿¡æ¯çš„é—®é¢˜ã€‚\n\n> [!failure] Limitations & Critiques\n> *Where can I improve upon this?*\n> - **ç»„ç»‡è§£ç¦»åå·®**: ä¼ ç»Ÿçš„ scRNA-seq è§£ç¦»æ­¥éª¤å®¹æ˜“å¯¼è‡´è„†å¼±ç»†èƒï¼ˆå¦‚æ³¡æ²«ç»†èƒã€æŸäº›ç‚ç—‡ç»†èƒï¼‰çš„ä¸¢å¤±æˆ–äººä¸ºæ¿€æ´»åº”æ¿€åŸºå› ã€‚åº”æ›´å¤šé‡‡ç”¨ [[snRNA-seq]] æˆ–ç©ºé—´æŠ€æœ¯äº’è¡¥ã€‚\n> - **åˆ†æå¤æ‚æ€§**: æ‰¹æ¬¡æ•ˆåº”ï¼ˆBatch Effectï¼‰å¤„ç†å¯èƒ½ä¼šå»é™¤çœŸå®çš„ç”Ÿç‰©å­¦å˜å¼‚ï¼›ä¸åŒè½¯ä»¶/å‚æ•°å¯¼è‡´çš„èšç±»ç»“æœä¸ä¸€è‡´ã€‚\n> - **å¤šç»„å­¦æ•´åˆéš¾åº¦**: ç›®å‰è·¨æ¨¡æ€ï¼ˆå¦‚ RNA + ATAC + è›‹ç™½ï¼‰æ•°æ®çš„æ•´åˆç®—æ³•åœ¨åˆ†è¾¨ç‡å’Œé¢„æµ‹å‡†ç¡®æ€§ä¸Šä»æœ‰å±€é™ã€‚\n\n> [!tip] Relevance to My Research\n> **Connection to [[FBN1]] or [[SPP1]]**:\n> - **[[SPP1]] (Osteopontin)**: æ–‡ä¸­æ˜ç¡®æåˆ° [[TREM2]] high å·¨å™¬ç»†èƒåœ¨äººç±»è¡€ç®¡å‘¨å›´è„‚è‚ªç»„ç»‡ä¸­è¢«é‰´å®šä¸º [[SPP1]]+ å·¨å™¬ç»†èƒï¼Œå¹¶ä¸çº¤ç»´åŒ–å’Œå† çŠ¶åŠ¨è„‰ç‹­çª„è´Ÿæ‹…ç›¸å…³ã€‚è¿™æ˜¯ä¸€ä¸ªå…³é”®çš„ç—…ç†äºšç¾¤ã€‚\n> - **[[FBN1]]**: è™½ç„¶æ–‡ä¸­æœªæ·±å…¥å±•å¼€ FBN1ï¼Œä½†åœ¨è®¨è®ºåŠ¨è„‰ç˜¤ï¼ˆAneurysmï¼‰å’Œ SMC è¡¨å‹è½¬æ¢ï¼ˆPhenotypic Switchingï¼‰æ—¶ï¼Œç»†èƒå¤–åŸºè´¨ï¼ˆECMï¼‰é‡å¡‘æ˜¯æ ¸å¿ƒæœºåˆ¶ï¼ŒFBN1 æ˜¯å…³é”®çš„ ECM æˆåˆ†ï¼Œå•ç»†èƒæ•°æ®å¸¸ç”¨äºåˆ†æ ECM ç›¸å…³åŸºå› æ¨¡å—çš„æ”¹å˜ã€‚\n> - *Idea to steal*: å€Ÿé‰´ Fig 7 çš„æµç¨‹ï¼Œåˆ©ç”¨ç°æœ‰çš„ scRNA-seq æ•°æ®ç»“åˆ GWAS ä¿¡å·ï¼Œä½¿ç”¨ [[MAGMA]] æˆ– [[scDRS]] è¯„åˆ†ï¼Œè¯„ä¼°ç‰¹å®šåŸºå› ï¼ˆå¦‚ FBN1 ä¸‹æ¸¸é€šè·¯ï¼‰åœ¨ç‰¹å®šç»†èƒäºšç¾¤ä¸­çš„ç–¾ç—…ç›¸å…³æ€§å¯Œé›†ã€‚\n\n## 5. Manuscript Snippets\n*Useful academic phrases or sentence structures to reference later*\n- \"Almost 200 years of histological and molecular analysis has established that functional shifts in vascular cell populations are associated with healthy vascular function...\" (ç”¨äº Introduction èƒŒæ™¯ä»‹ç»)\n- \"Single-cell approaches are becoming indispensable and powerful avenues for discovering and detailing new mechanisms of vascular disease.\" (ç”¨äºç»“è¯­)\n- \"Emerging evidence increasingly points to vascular inflammation as a key contributor to atherosclerotic vascular diseases...\" (æè¿°ç‚ç—‡èƒŒæ™¯)\n\n## 6. References\n- **Related Papers**:\n    - [[Kalluri et al., 2019]] (Mouse aorta atlas, identified EC heterogeneity)\n    - [[Wirka et al., 2019]] (SMC phenotypic switching to fibromyocytes, TCF21 role)\n    - [[Cochain et al., 2018]] (Macrophage heterogeneity in atherosclerosis)\n    - [[Tucker et al., 2020]] (Human heart snRNA-seq)\n- **Cited By**:\n    - [[ ]]"
  }
]